Abstract: A flyback converter is provided, which includes a transformer comprising a primary winding and a secondary winding, the transformer for transforming a power inputted from an input power supply and outputting the transformed power, a switching part having one end connected to the primary winding and the other end connected to the input power supply, and an auxiliary circuit including an auxiliary capacitor, and an auxiliary winding coupled to the primary winding. In addition, a clamping diode and a two-series connected switch structure is utilized for the switch stage to relieve the voltage stress of the switch. Accordingly, it is possible to reduce the voltage stress of the switch and also reduce the ripple of the input current which are the causes of EMI.

Abstract: The present disclosure relates to a process for obtaining an ultrapure polymer by simply and effectively removing unreacted residual monomer in polymer, which is generated during production of a biodegradable polymer such as polylactic acid or derivatives thereof.

Abstract: The present invention relates to a novel method for preparing cabazitaxel from 10-deacetylbaccatin III, and a novel intermediate therefor, and more specifically, to: a method which allows cabazitaxel to be more easily prepared in a high yield and in a high purity within a short time compared with a conventional method by preparing cabazitaxel via a novel intermediate using 10-deacetylbaccatin III as a starting material, and thus is suitable for industrial mass production; and a novel intermediate therefor.

Abstract: The present invention relates to a novel method for preparing cabazitaxel from 10-deacetylbaccatin III, and a novel intermediate therefor, and more specifically, to: a method which allows cabazitaxel to be more easily prepared in a high yield and in a high purity within a short time compared with a conventional method by preparing cabazitaxel via a novel intermediate using 10-deacetylbaccatin III as a starting material, and thus is suitable for industrial mass production; and a novel intermediate therefor.

Abstract: Provided are an extended release preparation for oral administration of bosentan including bosentan, a pharmaceutically acceptable salt thereof or a solvate thereof as an active ingredient and a hydrophilic polymer as a sustained release excipient, and a method of manufacturing the same. Accordingly, the number of administrations of the bosentan, a pharmaceutically acceptable salt thereof or a solvate thereof may be reduced, thereby enhancing ease of administration and patient compliance. In addition, the extended release preparation for oral administration of bosentan may be effectively manufactured.

Abstract: A pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof, which is capable of treating or preventing side effects such as muscle toxicity caused by administering a statin-based lipid-lowering drug, and a pharmaceutical combination composition comprising a statin drug and a losartan drug as active ingredients are provided. The pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof provides an effect on treating or preventing muscle-related side effects caused by administration of a statin drug for treating hyperlipidemia, as well as an intrinsic pharmacological effect for treating or preventing hypertension. When administered along with a statin drug in sequence or co-administered at the same time with the statin drug, the pharmaceutical composition can exhibit an effect of effectively or significantly decreasing or preventing side effects such as muscle toxicity.

Abstract: A magnetic flux coupling-type superconducting current limiter is capable of protecting lines more effectively by winding reactors of a primary coil and a secondary coil in series in the structure where the primary coil and the secondary coils are wound in parallel in the conventional magnetic flux-lock type current limiter to increase a linked flux generated from an iron core. An electric conducting current which rapidly increases when a fault occurs is divided into the secondary coil and a superconducting coil to decrease a load on the superconducting element and it is opened more rapidly than the existing superconducting current limiter during a quench time such that it better limits a fault current.

Abstract: A magnetic flux coupling-type superconducting current limiter is capable of protecting lines more effectively by winding reactors of a primary coil and a secondary coil in series in the structure where the primary coil and the secondary coils are wound in parallel in the conventional magnetic flux-lock type current limiter to increase a linked flux generated from an iron core. An electric conducting current which rapidly increases when a fault occurs is divided into the secondary coil and a superconducting coil to decrease a load on the superconducting element and it is opened more rapidly than the existing superconducting current limiter during a quench time such that it better limits a fault current.